iiinova — where your digital self keeps evolving

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 03/07/2025

More than proud to be working @nkinl.bsky.social under the great leadership of @thijnbrummel.bsky.social. His achievements in the field of fundamental sciences ✍️🔬are truly amazing! Congrats Thijn🥳

030

Reposted by Marleen Kok, MD PhD, NKI

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 15/05/2025

#ESMOBreast25: Low baseline tumour infiltrating lymphocytes #TILs and nodal involvement may predict #BreastCancer patients with poor prognosis despite pathological complete response to neoadjuvant chemotherapy. #ESMODailyReporter has more 🔗 buff.ly/YmxaCJ7

011

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 15/05/2025

I just learned a new pathologist joke: “Tumors dont read J Clin Oncol” from Beppe Viale cited by Carsten Denkert. 🧐📔We as researchers oversimplify cancer biology but tumors dont always follow our classifications @myesmo.bsky.social #esmoambassadors #esmobreast25

041

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 15/05/2025

Thanks to Nadia Harbeck 🙏for the following extremely important remarks: 1) we shouldnt aim for using even 2 gene expression test, one expensive test is enough; 2) instead use a dynamic biomarker: Ki67 drop after endocrine tx. @myesmo.bsky.social #esmoambassadors #esmobreast25

061

Reposted by Marleen Kok, MD PhD, NKI

Philippe Aftimos, MD @aftimosp.bsky.social · 14/05/2025

An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example #ESMOAmbassadors @myesmo.bsky.social

173

Reposted by Marleen Kok, MD PhD, NKI

Philippe Aftimos, MD @aftimosp.bsky.social · 14/05/2025

The path forward for immunotherapy biomarkers in breast cancer by @marleenkok.bsky.social #ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social

073

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 15/05/2025

Really impressive talk by Davide Massa on prognostic value of TILs together with nodal status in patients with TNBC and pCR. Outcome for TIL low and cN+ is not that good. Would additional treatment help? @myesmo.bsky.social #ESMOBreast25 #ESMOAmbassadors

061

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 12/05/2025

Do you want to know the most recent ins and outs in breast cancer research and treatment? Follow us 👇for the coolest news from #ESMOBreast25 #BCSM @myesmo.bsky.social

050

Reposted by Marleen Kok, MD PhD, NKI

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 17/04/2025

📢 #ESMOFellowship applications are now open! The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch and #ClinicalResearch projects. 📅 Apply by: 29 May 2025 🔗 buff.ly/NN5Y1ol

054

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 15/04/2025

Very very proud of you my friend. You are a star and fantastic scientist!

120

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 15/04/2025

Please donate!🚵🏽‍♂️💵💰 Last year we received a huge grant 🤩from KWF to launch the internat OPTImaL trial to avoid chemo for low stage BC with many immune cells! We strongly feel that we should do something in return for KWF so we will bike 🚵🏽‍♂️the Alpe d’Huez 💪🏼 www.opgevenisgeenoptie.nl/fundraisers/...

opgevenisgeenoptie.nl

Marleen Kok

Ik doe mee aan Alpe d’HuZes omdat ik geloof dat wij samen kunnen werken aan een wereld waarin je niet meer doodgaat aan kanker, wil jij mij steunen?

010

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 13/03/2025

Thanks @drsgraff.bsky.social for your amazing report of -again- an amzing session #SGBCC2025

060

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 01/03/2025

With co-director @vkaklamani.bsky.social of @sabcs.bsky.social we have been working on #SABCS25 program! Stay tuned! Super exciting with stellar line-up of speakers. With @heidefordlab.bsky.social @itsnotpink.bsky.social and many other fantastic faculty members #bcsm

172

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 25/02/2025

Looking forward to work as senior editor for the @theaacr.bsky.social journal Clin Cancer Res with this 👇 amazing editor-in-chief. Congrats Tim Yap!

020

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 07/02/2025

very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm

074

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 07/02/2025

Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️

032

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 10/01/2025

Impressive paper on biomarkers for immunotherapy in RCC! Good to see biomarkers from pharma-sponsored clinical trials!

020

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 03/01/2025

Interesting paper on neo-antigen specific T cell therapy! Congrats Cell Therapy team @nkinl.bsky.social

082

Reposted by Marleen Kok, MD PhD, NKI

Jon Lim, FRCP PhD @drjonlim.bsky.social · 11/12/2024

Big fan of the concept of immunogenic cell death/inducing immunogenicity with 'conventional' therapies - so really looking forward to reading/hearing more about TONIC2 following the nice work from the original TONIC trial by @marleenkok.bsky.social & team @nkinl.bsky.social 👇

041

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 10/12/2024

Smart analyses approach in immunotherapy trials #SABCS24 with stellar 🤩 scientists @christinedesmedt.bsky.social @lambrechtslab.bsky.social C. Sotiriou, R. Ali and E. Romero

020

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 10/12/2024

Great start #SABCS24 with session on Dietary Suppl, Sex, Exercise ‘Sex, Drugs and Rock n Roll’ 💊🍺❤️🏃🏽‍♂️‍➡️with funny joke by @drdonsdizon.bsky.social that his talk will be a ‘quickie’🤣

050

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 09/12/2024

#SABCS24 is a good test who and how many breast cancer research folks decided wisely to move to from X to @bsky.app 🧐. Looking forward to lively comments on the exciting new data we will see in the coming days @oncoalert.bsky.social @oncbrothers.bsky.social @oncodaily.bsky.social

040

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 05/12/2024

Recent Nature paper on phase of menstrual cycle at start of breast cancer chemo suggests that this can affect chemo-sensitivity. More research needed on how this can result in cycle-driven-chemo-start. 💊💉Congrats ⁦‪@vanRheenen_Lab‬⁩ ⁦‪@NKI_nl‬⁩ rdcu.be/d2p2l

rdcu.be

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy

Nature - In three mouse models of breast cancer, we show reduced responses to neoadjuvant chemotherapy when treatment is initiated during the dioestrus stage, when compared with initiation during...

050

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 02/12/2024

The PhD program @nkinl.bsky.social is excellent! NKI is the place to be for top-notch cancer research while working in a fantastic open and friendly atmosphere👇

041

Reposted by Marleen Kok, MD PhD, NKI

Elisa Agostinetto @elisaagostinetto.bsky.social · 27/11/2024

The results of the SONIA trial on the early vs deferred use of CDK4/6i in advanced breast cancer are now published in @Nature No statistically significant benefit for the use of CDK4/6i as a first-line compared with second-line treatment @oncoalert.bsky.social www.nature.com/articles/s41...

nature.com

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature

The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.

084

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 22/11/2024

Insightful translational study on chemo+IO in eTNBC dissecting chemo response vs IO response! Well done GBG! @cellpressnews.bsky.social #bcsm @oncoalert.bsky.social

0102